Role of Gut Microbial Translocation in Initiating Autoimmunity

肠道微生物易位在启动自身免疫中的作用

基本信息

  • 批准号:
    10291780
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-10-01 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

Genetic and environmental factors contribute to systemic lupus erythematosus (SLE). Previous studies showed environmental factors such as bacterial products or their-induced inflammatory mediators (e.g., IFN-α) are involved in SLE pathogenesis. Previous studies from others and we revealed that multiple autoAbs are more commonly detected in first-degree relatives of lupus patients (FDRs), compared to unrelated healthy controls (UHCs). In addition, FDRs have heightened levels of inflammation (e.g., B lymphocyte stimulator (BLyS), and IFN-α) associated with TLR stimulation and B cell activation compared with UHCs. It is unclear the initial trigger for autoantibody production. This lack of understanding of early events in development of autoimmunity is a critical barrier for disease prevention. FDRs, rather than patients, provide a study population, genetically prone and possibly environmentally exposed, who are not on immune modulatory drugs nor impacted by disease, allowing conclusions less confounded by external factors. In preliminary studies, we found: 1) increased presence and diversity of autoAbs in healthy FDRs of lupus patients compared to unrelated healthy controls (UHCs); 2) increased microbial product translocation (plasma LPS) associated with elevated plasma autoAb levels (anti-dsDNA, anti-ssDNA, and anti-nucleosome); and 3) decreased plasma microbial diversity in FDRs with enrichment of the family Streptococcaceae and genus of Streptococcus product translocation in UHCs and relative enrichment of Pseudomonas product translocation in FDRs relative to UHCs. Recently SNPs in the coding region of two genes that mediate gut permeability were identified as associated with lupus disease risk. We hypothesize that increased gut microbial product translocation and its-associated inflammation in FDR individuals, a result of a “leaky” gut, serve as initiators for autoAb production and later SLE development. In the current study, we will recruit matched UHCs, FDRs, and lupus patients. A “leaky” gut leading to systemic bacterial products and autoAb induction in the pathogenesis of lupus represents a novel mechanism to explain disease initiation in susceptible genetic high- risk individuals. Specific Aim 1: Determine intestinal barrier integrity, systemic bacterial product translocation, and its mediated inflammation in the activation of B cells. We hypothesize that plasma autoAb levels are associated with intestinal barrier integrity, inflammation and systemic bacterial products. In vivo gut permeability tests, plasma LPS and total bacterial rDNA levels, plasma TLR-related inflammation (e.g., IL-6 and IFN-α), B cell subset activation and a series of lupus-related autoAbs (e.g., anti-dsDNA and anti-nucleosome IgGs) will be assessed in patients, FDRs and UHCs. Specific Aim 2: Determine systemic and mucosal microbial components and the effect of certain bacterial product translocation on autoantibody production. We have observed relative enrichment of Pseudomonas products in plasma of FDRs relative to UHCs. Comparisons between systemic and mucosal microbiomes has not been reported previously in lupus patients, FDRs or UHCs. We therefore will assess the systemic and mucosal microbiome and identify the role of microbial translocation in autoAb production and lupus disease in both human and mouse studies. In the current study, we propose to investigate a novel mechanism for autoAb production and SLE etiology. We believe that a broad array of TLR agonists, from a “leaky” gut, are the fundamental drivers of autoAb initiation. This work will provide insight into the potential of a therapeutic strategy targeting mucosa or particular bacteria to prevent autoAbs and disease onset.
遗传和环境因素有助于系统性红斑狼疮(SLE)。以前的研究表明 环境因素如细菌产物或它们诱导的炎症介质(例如,IFN-α) 参与SLE发病机制。其他人和我们以前的研究表明,多个autoAb 与无关的健康对照相比,在狼疮患者的一级亲属(FDR)中常见 (UHC)。此外,FDR具有升高的炎症水平(例如,B淋巴细胞刺激因子(BLyS),和 与UHC相比,IFN-α与TLR刺激和B细胞活化相关。目前尚不清楚最初的触发因素 用于自身抗体的产生。对自身免疫发展的早期事件缺乏了解, 是预防疾病的重要屏障。FDR,而不是患者,提供了一个研究人群, 并且可能暴露于环境中,他们没有服用免疫调节药物,也没有受到疾病的影响, 从而使结论较少受到外部因素的干扰。 在初步研究中,我们发现:1)在狼疮的健康FDR中,autoAb的存在和多样性增加 与无关的健康对照(UHC)相比,患者; 2)增加微生物产物易位(血浆 LPS)与升高的血浆自身抗体水平(抗dsDNA、抗ssDNA和抗核小体)相关;和3) FDR中血浆微生物多样性降低,链球菌科和链球菌属富集 链球菌产物在UHC中的易位和假单胞菌产物在UHC中的相对富集 相对于UHC的FDR。最近,在两个调节肠道通透性的基因编码区的SNP被发现, 与狼疮疾病风险相关。我们假设增加的肠道微生物产物 FDR个体中的易位及其相关炎症,由于“泄漏”肠道, autoAb生产和后来SLE发展的启动子。在目前的研究中,我们将招募匹配的 UHC,FDR,和狼疮患者。“渗漏”肠道导致全身性细菌产物和autoAb诱导, 狼疮的发病机制代表了一种新的机制,可以解释易感遗传性高- 风险个人。 具体目标1:确定肠屏障完整性、全身性细菌产物移位及其 在B细胞活化中介导炎症。我们假设血浆自身抗体水平与 肠道屏障完整性、炎症和全身细菌产物。体内肠道渗透性试验, 血浆LPS和总细菌rDNA水平,血浆TLR相关炎症(例如,IL-6和IFN-α),B细胞 亚群激活和一系列狼疮相关的自身抗体(例如,抗dsDNA和抗核小体IgG)将被 在患者、FDR和UHC中进行评估。 具体目标2:确定全身和粘膜微生物成分以及某些 细菌产物易位对自身抗体产生的影响。我们观察到相对富集的 相对于UHC,FDR血浆中的假单胞菌产物。全身和粘膜之间的比较 在狼疮患者、FDR或UHC中以前没有报道过微生物组。因此,我们将评估 系统和粘膜微生物组,并确定微生物易位在自身抗体产生和狼疮中的作用 在人类和小鼠的研究中。 在目前的研究中,我们提出了一种新的机制,autoAb生产和SLE病因。我们 相信来自“渗漏”肠道的一系列广泛的TLR激动剂是autoAb起始的基本驱动因素。 这项工作将提供深入了解的潜在治疗策略针对粘膜或特定的细菌 以防止自身抗体和疾病发作。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gary S Gilkeson其他文献

Podocytes: A Potential Source of Nitric Oxide Production in Murine Lupus Nephritis
  • DOI:
    10.1016/j.freeradbiomed.2010.10.406
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ahmad K Mashmoushi;Ann F Hofbauer;Gary S Gilkeson;Jim C Oates
  • 通讯作者:
    Jim C Oates
Role of Nitric Oxide in Podocyte Physiology in Lupus Nephritis
  • DOI:
    10.1016/j.freeradbiomed.2012.10.228
  • 发表时间:
    2012-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Ahmad K Mashmoushi;Ann F Hofbauer;Gary S Gilkeson;Jim C Oates
  • 通讯作者:
    Jim C Oates
Human SLE variant NCF1-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages
  • DOI:
    10.1136/annrheumdis-2021-220793.
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
  • 作者:
    Linyu Geng;Jian Zhao;Yun Deng;Ivan Molano;Xue Xu;Lingxiao Xu;Phillip Ruiz;Quanzhen Li;Xuebing Feng;Miaojia Zhang;Wenfeng Tan;Diane L Kamen;San-Cheol Bae;Gary S Gilkeson;Lingyun Sun;Betty P Tsao
  • 通讯作者:
    Betty P Tsao
PSS61 - Nitric Oxide Modulation of Redox-Modulated Cytokines in Lupus Nephritis
  • DOI:
    10.1016/j.freeradbiomed.2013.10.476
  • 发表时间:
    2013-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jim C Oates;Ahmad K Mashmoushi;Ann F Hofbauer;Gary S Gilkeson
  • 通讯作者:
    Gary S Gilkeson
Human SLE variant emNCF1/em-R90H promotes kidney damage and murine lupus through enhanced Tfh2 responses induced by defective efferocytosis of macrophages
人类系统性红斑狼疮变异体 emNCF1/em-R90H 通过巨噬细胞吞噬缺陷导致的 Tfh2 反应增强促进肾脏损伤和小鼠狼疮
  • DOI:
    10.1136/annrheumdis-2021-220793
  • 发表时间:
    2022-02-01
  • 期刊:
  • 影响因子:
    20.600
  • 作者:
    Linyu Geng;Jian Zhao;Yun Deng;Ivan Molano;Xue Xu;Lingxiao Xu;Phillip Ruiz;Quanzhen Li;Xuebing Feng;Miaojia Zhang;Wenfeng Tan;Diane L Kamen;Sang-Cheol Bae;Gary S Gilkeson;Lingyun Sun;Betty P Tsao
  • 通讯作者:
    Betty P Tsao

Gary S Gilkeson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gary S Gilkeson', 18)}}的其他基金

A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
同种异体间充质干细胞治疗难治性狼疮的 II 期对照试验
  • 批准号:
    10827646
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
同种异体间充质干细胞治疗难治性狼疮的 II 期对照试验
  • 批准号:
    10356843
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Improving Minority Health in Rheumatic Diseases
改善少数民族风湿病健康
  • 批准号:
    9902868
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Improving Minority Health in Rheumatic Diseases
改善少数民族风湿病健康
  • 批准号:
    10254241
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Improving Minority Health in Rheumatic Diseases
改善少数民族风湿病健康
  • 批准号:
    9413805
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10254245
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Role of Gut Microbial Translocation in Initiating Autoimmunity
肠道微生物易位在启动自身免疫中的作用
  • 批准号:
    9564333
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Mesenchymal Stem Cell Therapy for Active Systemic Lupus Erythematosus
间充质干细胞治疗活动性系统性红斑狼疮
  • 批准号:
    8791443
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Sex Differences in Gut Permeability; Impact on Autoimmunity
肠道渗透性的性别差异;
  • 批准号:
    8958705
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Sex Differences in Gut Permeability; Impact on Autoimmunity
肠道渗透性的性别差异;
  • 批准号:
    8820340
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了